Methods for Treating Premature Newborn Infants by Administration of Recombinant Human Surfactant Protein D (rhSP-D)
AssigneeAirway Therapeutics, Inc.
InventorsRaquel Arroyo Rodriguez, Marc Salzberg
Life of this patent
Estimating the term…
Loading patent…
AssigneeAirway Therapeutics, Inc.
InventorsRaquel Arroyo Rodriguez, Marc Salzberg
Estimating the term…
A method for reducing the duration of mechanical ventilation in a premature infant at risk for developing bronchopulmonary dysplasia (BPD) includes administering an effective amount of recombinant human surfactant protein D (rhSP-D) to the infant. In further aspects a method for reducing the duration of days in a hospital in a premature infant at risk for developing BPD includes administering an effective amount of rhSP-D to the infant. In certain aspects a method for reducing a probability that a premature infant at risk for developing BPD will develop one or more secondary comorbidities of prematurity includes administering an effective amount of recombinant human surfactant protein D (rhSP-D) to the infant. Pharmaceutical compositions for use in the described methods and uses of a pharmaceutical composition are also described.
A method for reducing the duration of mechanical ventilation in a premature infant at risk for developing bronchopulmonary dysplasia (BPD), comprising administering an effective amount of recombinant human surfactant protein D (rhSP-D) to the infant.
A method for reducing the duration of days in a hospital in a premature infant at risk for developing BPD, comprising administering an effective amount of rhSP-D to the infant.
A method for reducing a probability that a premature infant at risk for developing BPD will develop one or more secondary comorbidities of prematurity, comprising administering an effective amount of recombinant human surfactant protein D (rhSP-D) to the infant.
Use of a pharmaceutical composition in (1) reducing the duration of mechanical ventilation in a premature infant at risk for developing bronchopulmonary dysplasia (BPD), (2) reducing the duration of days in a hospital in a premature infant at risk for developing BPD, or (3) reducing a probability that a premature infant at risk for developing BPD will develop one or more secondary comorbidities of prematurity,
Dependencies are inferred from the claim text.